Akebia Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 56.2 million compared to USD 55.78 million a year ago. Net income was USD 0.613 million compared to net loss of USD 6.07 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9892 USD | +6.98% | +5.23% | -20.23% |
06-24 | Akebia Therapeutics Names Erik Ostrowski CFO, CBO | MT |
06-24 | Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.23% | 194M | |
+16.13% | 122B | |
+19.65% | 115B | |
+21.22% | 26.64B | |
-23.84% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-19.28% | 15.49B | |
+63.81% | 14.83B | |
+1.94% | 13.67B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023